(Q38154915)

29 August 2017

title

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic (English)

1 reference

29 August 2017

4

Eva J Brandl

1 reference

29 August 2017

Daniel J Müller

1

1 reference

29 August 2017

Ivana Kekin

series ordinal

2

1 reference

29 August 2017

Amy C C Kao

series ordinal

3

1 reference

29 August 2017

publication date

1 October 2013

1 reference

International Review of Psychiatry

29 August 2017

published in

1 reference

29 August 2017

volume

25

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

554-571

1 reference

Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Cross-national epidemiology of DSM-IV major depressive episode

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Genetics and personalized medicine in antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Using a pharmacogenomic algorithm to guide the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

CYP2C19 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The pharmacogenetics of antipsychotic-induced adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Will a new genotyping test help the clinician predict response to antidepressant drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

CYP2D6 and the severity of suicide attempts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Pharmacogenetics: from bench to byte--an update of guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Clinical pharmacokinetics of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Pharmacogenetics of anxiolytic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Is pharmacogenetic CYP2D6 testing useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Polymorphism of human cytochrome P450 enzymes and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.838944

10.3109/09540261.2013.838944

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference